Demystifying Medicine: Fibrosis: Inflammation and Cirrhosis with Thomas Anthony Wynn, PhD and Theo Heller, MD

Date: Tuesday, 03 21, 2017; Speaker: Thomas Anthony Wynn, PhD , NIAID; Theo Heller, MD, NIDDK; Building: Building 50; Conference Room 1227; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events

Related Links:

Authors: Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, Rai S, Nakayama S, Serizawa K, Kumode T, Watatani Y, Morita Y, Tanaka H, Matsumura I Abstract We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL afte...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 9 July 2020Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Simona Tripon, Pierre Mayer, Axenia Svab, François Habersetzer, Patrick Pessaux, Thomas F. Baumert, Iulian Enescu
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
We read with great interest the article by Trebicka and colleagues1 in which they report a higher rebleeding rate and poor outcomes of acute variceal bleeding (AVB) in patients with acute-on-chronic liver failure (ACLF); they report that pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) improves outcomes in such patients. In their earlier analysis using the same database, the same group suggested pTIPS to be the treatment of choice in high-risk patients with Child-Pugh class C cirrhosis and AVB.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
AbstractIntroductionIn hepatitis C (HCV) patients, obesity and/or diabetes may increase the risk of liver-related outcomes. We aimed to determine whether diabetes and/or obesity are associated with adverse outcomes in direct-acting antiviral (DAA)-treated HCV patients.MethodsWe conducted a retrospective study of 33,003 HCV-infected, DAA-treated Veterans between 2013 and 2015. Body mass index was used to categorize patients into underweight (
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Conditions:   Sarcopenia;   Sarcopenic Obesity;   Cirrhosis, Liver Intervention:   Other: none intervention type Sponsor:   University of Roma La Sapienza Recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 10 July 2020Source: Respiratory Medicine Case ReportsAuthor(s): Asma Migaou, Ahmed Ben Saad, Hassene Baili, Saoussen Cheikh Mhamed, Asma Achour, Wided Bouhlel, Nesrine Fahem, Mabrouk Abdelaaly, Naceur Rouatbi, Samah Joobeur
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Conditions:   Sarcopenia;   Sarcopenic Obesity;   Cirrhosis, Liver Intervention:   Other: none intervention type Sponsor:   University of Roma La Sapienza Recruiting
Source: - Category: Research Source Type: clinical trials
(Osaka University) Mesenchymal stem cell (MSC) therapy has shown promising results in the treatment of conditions ranging from liver cirrhosis to retinal damage, but results can be variable. Using a mouse heart failure model, researchers led by Osaka University found that levels of a fat cell-derived hormone called adiponectin in the host significantly affect the efficacy of MSC therapy. Administration of a drug that increases adiponectin in combination with MSCs is therefore likely to significantly improve the clinical outcome.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Umbilical cord mesenchymal stem cells (UCMSCs) have been demonstrated to have good therapeutic effects in the treatment of HBV-related liver diseases. However, the therapeutic effect of UCMSCs on HBV-related l...
Source: Stem Cell Research and Therapy - Category: Stem Cells Authors: Tags: Research Source Type: research
AbstractPurpose of ReviewCirrhotic cardiomyopathy is a syndrome of depressed cardiac function in patients with cirrhosis. We aimed to review the historical background, pathophysiology and pathogenesis, diagnostic definitions, clinical relevance, and management of this syndrome.Recent FindingsAn inflammatory phenotype underlies the pathogenesis: gut bacterial translocation with endotoxemia stimulates cytokines and cardiodepressant factors, such as nitric oxide and endocannabinoids. Cardiomyocyte plasma membrane biochemical and biophysical changes also play a pathogenic role. These factors lead to impaired beta-adrenergic fu...
Source: Current Gastroenterology Reports - Category: Gastroenterology Source Type: research
More News: American Health | Cirrhosis | Conferences